SCHEMBL7913600

SCHEMBL7913600

Cn1nc2c(c1C(=O)O)CCCc1cccnc1-2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 1/20 0.36
PTAFR P25105 7/20 0.36
HRH1 P35367 3/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
ADRA1A P35348 1/20 0.35
OPRK1 P41145 1/20 0.35
HTR2B P41595 1/20 0.35
KCNH2 Q12809 1/20 0.35
PARP1 P09874 1/20 0.35
MCL1 Q07820 1/20 0.34
RXRA P19793 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7911087 0.80 CDK2 (0.49) PTAFRMYCTTK
SCHEMBL12240651 0.79 GRM5 (0.53) POLB
SCHEMBL7909158 0.72 CCNA2 (0.37) PTAFRHRH1CHRM2HTR1ACHRM1
SCHEMBL4912110 0.72 TSHR (0.43) TDP1L3MBTL1KDM4EPTAFRHRH1
SCHEMBL2548366 0.71 CDK2 (0.57) PTAFRTTK
SCHEMBL14804863 0.69 GSR (0.47) TDP1POLBMAPTL3MBTL1KDM4E
SCHEMBL32691466 0.68 DRD4 (0.47) POLBMAPTL3MBTL1KDM4EDRD4
SCHEMBL23062881 0.68 POLB (0.93) TDP1POLBMAPTL3MBTL1KDM4E
SCHEMBL16341636 0.68 TDP1 (0.40) TDP1POLBMAPTL3MBTL1KDM4E
SCHEMBL10628560 0.65 KDM4E (0.56) TDP1POLBMAPTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GRM5, GRM1, GRM3 TDP1 2656/4885POLB 4360/4885MAPT 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.